Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Hold at BidaskClub

BidaskClub downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a report published on Wednesday, May 30th.

Several other equities analysts also recently commented on COLL. HC Wainwright boosted their target price on shares of Collegium Pharmaceutical from $21.00 to $33.00 and gave the stock a buy rating in a report on Thursday, March 8th. Janney Montgomery Scott set a $26.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a report on Tuesday, February 6th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Friday, February 2nd. Jefferies Financial Group boosted their target price on shares of Collegium Pharmaceutical to $32.00 and gave the stock a buy rating in a report on Monday, February 12th. Finally, Piper Jaffray Companies set a $33.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average price target of $32.14.

Collegium Pharmaceutical opened at $26.32 on Wednesday, according to Marketbeat. The company has a market capitalization of $824.78 million, a price-to-earnings ratio of -10.66 and a beta of 0.73. Collegium Pharmaceutical has a 1-year low of $9.01 and a 1-year high of $29.90. The company has a debt-to-equity ratio of 3.91, a current ratio of 0.83 and a quick ratio of 0.80.



Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). The firm had revenue of $63.70 million during the quarter, compared to the consensus estimate of $51.92 million. Collegium Pharmaceutical had a negative return on equity of 72.87% and a negative net margin of 78.22%. The business’s revenue for the quarter was up 2835.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.79) earnings per share. equities research analysts anticipate that Collegium Pharmaceutical will post -1.23 earnings per share for the current fiscal year.

In related news, Chairman Michael Thomas Heffernan sold 44,400 shares of the company’s stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $26.00, for a total transaction of $1,154,400.00. Following the sale, the chairman now owns 545,893 shares of the company’s stock, valued at $14,193,218. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alison B. Fleming sold 4,096 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $27.00, for a total transaction of $110,592.00. Following the sale, the insider now directly owns 53,362 shares in the company, valued at approximately $1,440,774. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 278,179 shares of company stock worth $6,855,531. 13.87% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in COLL. Wellington Shields Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $204,000. EagleClaw Capital Managment LLC purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $220,000. Stifel Financial Corp purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $224,000. Acadian Asset Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $176,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at $260,000. 92.77% of the stock is currently owned by institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply